NCT00428545View on ClinicalTrials.gov

Bevacizumab and Bortezomib in Patients With Advanced Malignancy

PHASE1CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
Advanced MalignancyLymphomaMyelomaSolid Tumors
Interventions
DRUG

Bevacizumab

Starting Dose 2.5 mg/kg By Vein On Day 1 Every 21 Days

DRUG

Bortezomib

Starting Dose 0.7 mg/m\^2 By Vein On Days 1 and 8 Every 21 Days

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT00428545 - Bevacizumab and Bortezomib in Patients With Advanced Malignancy | Biotech Hunter | Biotech Hunter